Finch Therapeutics Group Stock Performance
| FNCH Stock | USD 2.31 0.48 17.20% |
On a scale of 0 to 100, Finch Therapeutics holds a performance score of 1. The firm shows a Beta (market volatility) of 1.01, which means a somewhat significant risk relative to the market. Finch Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Finch Therapeutics is expected to follow. Please check Finch Therapeutics' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Finch Therapeutics' price patterns will revert.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Finch Therapeutics Group are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental indicators, Finch Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (18.77) | Five Day Return (1.31) | Year To Date Return (40.84) | Ten Year Return (99.65) | All Time Return (99.65) |
Last Split Factor 1:30 | Last Split Date 2023-06-12 |
1 | FNCH Stock Earnings Finch Therapeutics Gr Reported Results for Q4 2023 - InvestorPlace | 03/25/2024 |
2 | Disposition of 6642 shares by Smisek Jeffery A of Finch Therapeutics at 2.57 subject to Rule 16b-3 | 03/28/2024 |
3 | Finch Therapeutics Group Full Year 2022 Earnings Misses Expectations - Yahoo Movies UK | 04/18/2024 |
| Begin Period Cash Flow | 71 M |
Finch |
Finch Therapeutics Relative Risk vs. Return Landscape
If you would invest 309.00 in Finch Therapeutics Group on January 25, 2024 and sell it today you would lose (30.00) from holding Finch Therapeutics Group or give up 9.71% of portfolio value over 90 days. Finch Therapeutics Group is currently generating 0.2336% in daily expected returns and assumes 9.3647% risk (volatility on return distribution) over the 90 days horizon. In different words, 82% of stocks are less volatile than Finch, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Finch Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Finch Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Finch Therapeutics Group, and traders can use it to determine the average amount a Finch Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0249
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FNCH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.36 actual daily | 82 82% of assets are less volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Finch Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Finch Therapeutics by adding it to a well-diversified portfolio.
Finch Therapeutics Fundamentals Growth
Finch Stock prices reflect investors' perceptions of the future prospects and financial health of Finch Therapeutics, and Finch Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Finch Stock performance.
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (317.78) % | ||||
| Current Valuation | 9.48 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K | ||||
| Gross Profit | (57.03 M) | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (74.75 M) | ||||
| Cash And Equivalents | 104.67 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 30.13 M | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 7.28 X | ||||
| Book Value Per Share | 14.25 X | ||||
| Cash Flow From Operations | (31.5 M) | ||||
| Earnings Per Share | (46.59) X | ||||
| Market Capitalization | 4.48 M | ||||
| Total Asset | 71 M | ||||
| Retained Earnings | (350.39 M) | ||||
| Working Capital | 21.76 M | ||||
About Finch Therapeutics Performance
To evaluate Finch Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Finch Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Finch Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Finch Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Finch's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (267.76) | (254.38) | |
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (1.05) | (1.11) | |
| Return On Equity | (3.27) | (3.10) |
Things to note about Finch Therapeutics performance evaluation
Checking the ongoing alerts about Finch Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Finch Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Finch Therapeutics had very high historical volatility over the last 90 days | |
| Finch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M). | |
| Finch Therapeutics Group currently holds about 104.67 M in cash with (31.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19. | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Finch Therapeutics Group Full Year 2022 Earnings Misses Expectations - Yahoo Movies UK |
- Analyzing Finch Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Finch Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Finch Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Finch Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Finch Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Finch Therapeutics' stock. These opinions can provide insight into Finch Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Finch Therapeutics Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Finch Therapeutics information on this page should be used as a complementary analysis to other Finch Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Finch Stock analysis
When running Finch Therapeutics' price analysis, check to measure Finch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Finch Therapeutics is operating at the current time. Most of Finch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Finch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Finch Therapeutics' price. Additionally, you may evaluate how the addition of Finch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Finch Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Finch Therapeutics. If investors know Finch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Finch Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (46.59) | Revenue Per Share 0.067 | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (1.26) |
The market value of Finch Therapeutics is measured differently than its book value, which is the value of Finch that is recorded on the company's balance sheet. Investors also form their own opinion of Finch Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Finch Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Finch Therapeutics' market value can be influenced by many factors that don't directly affect Finch Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Finch Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.